Nicholas Short, MD, University of Texas MD Anderson Cancer Center, Houston, TX, shares some updated results from a Phase II study evaluating the use of ponatinib and blinatumomab for the treatment of Ph+ acute lymphoblastic leukemia (ALL). Dr Short first discusses the high rates of measurable residual disease (MRD) negative responses observed, and then highlights the toxicity profile of this combination approach. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.
N.J.S. reports receiving research grants from Takeda Oncology, Astellas Pharma Inc., Stemline Therapeutics, Inc, and Xencor and has received honoraria from Amgen, Jazz Pharmaceuticals, Astellas Pharmac, Inc., Novartis and Pfizer.